Alpha Cognition Inc.
Alpha Cognition Inc. is a pre-NDA, biopharmaceutical company dedicated to developing treatments for patients suffering from Alzheimer’s disease and ALS. ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition and inflammation. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia.
Alpha Cognition Inc. (ACOG)
le 3 octobre/October 2023
Alpha Cognition Inc. - 1OCT2023 Warrants listed on May 1, 2023 expired on October 1, 2023.
Trading is currently halted.
The warrants will be delisted at market close October 3, 2023.
Alpha Cognition Inc. - 1OCT2023 Les bons de souscription cotés le 1er mai 2023 ont expiré le 1er octobre 2023.